Advertisement
Advertisement

BMRN

BMRN logo

BioMarin Pharmaceuticals Inc

54.15
USD
Sponsored
-0.47
-0.86%
Apr 22, 16:00 UTC -4
Closed
exchange

After-Market

54.18

+0.03
+0.06%

BioMarin Pharmaceuticals Inc Profile

About

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.?The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.

Info & Links

CEO

Alexander Hardy

Headquarters

770 Lindaro Street
San Rafael, CA 94901, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.biomarin.com

Auditor

KPMG LLP

Share holders

28

Employees

3,221

BioMarin Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization2

10.42B

Enterprise Value

9.71B

Enterprise Value/EBITDA(ttm)

20.04

Price to Earnings Ratio(ttm)

23.17

Price to Sales(ttm)

3.36

Price to Book(mrq)

1.78

Price to Cash(ytd)

19.73

Profitability

Gross Margin(ttm)

77.98%

Operating Margin(ttm)

14.70%

Profit Margin(ttm)

11.19%

Return on Equity(ttm)

7.91%

Return on Invested Capital(ttm)

5.38%

Return on Assets(ttm)

6.36%

Income Statement

Revenue(ttm)

3.22B

Revenue Per Share(ttm)

16.75

Gross Profit(ttm)

2.50B

EBITDA(ttm)3

484.23M

Net Income Available to Common(ttm)

348.90M

Diluted EPS(ttm)

1.78

Share Statistics

Beta (5Y Monthly)

0.29

52-Week Change

-7.67%

S&P 500 52-Week Change

34.99%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

192.32M

Dividend Yield

0.00%

Float4

190.69M

% Held by Insiders

0.85%

% Held by Institutions

98.71%

Balance Sheet

Total Cash(mrq)

1.56B

Total Cash Per Share(mrq)

8.11

Total Debt(mrq)

597.18M

Total Debt/Equity(mrq)

9.81%

Current Ratio(mrq)

5.21%

Quick Ratio(mrq)

3.50%

Book Value Per Share(mrq)

31.65

Cash Flow

Operating Cash Flow Per Share(ytd)

4.19

Free Cash Flow(ytd)

724.96M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement